vTv Therapeutics (VTVT) Enterprise Value (2015 - 2026)

vTv Therapeutics has disclosed Enterprise Value across 12 years of filings, most recently posting $380.6 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 424.73% year-over-year to $380.6 million; the TTM figure through Jun 2026 stood at $380.6 million (up 424.73% YoY), while the FY2025 annual figure was $247.9 million, up 451.4% from the prior year.
• Enterprise Value came in at $380.6 million for Q2 2026 at vTv Therapeutics, down from $394.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $394.1 million in Q1 2026 to a low of $27.2 million in Q4 2023.
• Average Enterprise Value over 5 years is $113.5 million, with a median of $73.5 million recorded in 2022.
• Year-over-year, Enterprise Value sank 76.13% in 2022 and soared 451.4% in 2025.
• Over 5 years, Enterprise Value stood at $73.8 million in 2022, then slumped by 63.07% to $27.2 million in 2023, then jumped by 65.08% to $45.0 million in 2024, then soared by 451.4% to $247.9 million in 2025, then soared by 53.5% to $380.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $380.6 million in Q2 2026, $394.1 million in Q1 2026, and $247.9 million in Q4 2025.